Non-viral gene therapy for Atrial Fibrillation

About Inomagen Therapeutics

Inomagen Therapeutics is a private, preclinical-stage biotech focused on transforming atrial fibrillation treatment through a proprietary non-viral gene therapy platform. The company has assembled an experienced leadership team with deep cardiovascular and gene therapy expertise and has been recognized in multiple pitch competitions, indicating strong external validation. Backed by non-dilutive grant funding and housed within the Portal Innovations incubator in Chicago, Inomagen is advancing its lead program toward clinical development to address a significant unmet need in a large, growing market.

Therapeutic Areas

Other Atrial Fibrillation Drugs